Omkar Speciality Chemicals Limited has provided prior intimation to the Bombay Stock Exchange and National Stock Exchange regarding an upcoming board meeting pursuant to Regulation 29 of SEBI (LODR) Regulations, 2015.
The Board of Directors meeting is scheduled for Friday, August 7, 2026, to consider and approve the following financial statements:
- Unaudited Financial Statements for the quarter September 2022 and December 2022, along with Audited Financial Statements for the year ended March 31, 2023
- Unaudited Financial Statements for all quarters and Audited Financial Statements for the year ended March 31, 2024
- Unaudited Financial Statements for all quarters and Audited Financial Statements for the year ended March 31, 2025
The company explains that it was unable to submit quarterly/half-yearly/yearly financial results from financial year 2022 to 2025 due to being under Corporate Insolvency Resolution Process (CIRP) under the provisions of Insolvency and Bankruptcy Code, 2016. The delay was primarily attributable to circumstances prevailing during CIRP, including resignation of Key Managerial Personnel, non-availability of records, and other operational constraints.
The disclosure confirms that trading in the company's equity shares remains suspended on both BSE Limited and the National Stock Exchange of India Limited. Due to the continuing suspension, the company has not issued a separate intimation regarding closure of the Trading Window for this board meeting, as the securities are not available for trading.
The letter is signed by Mahendra Kumar Jain, Additional Director (DIN: 09765526), on behalf of Omkar Speciality Chemicals Limited.